Conference Call Scheduled for today, September 30, 2024, at 5:00pm ET.
GARDNER, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its fourth quarter and fiscal year ended June 30, 2024.
FY 2024 Financial Highlights (Year Ended June 30, 2024):
- Revenue was $19.1 million compared to $21.0 million in the previous fiscal year. Revenue of $19.1 million, exceeded the high end of the expected range announced on August 14, 2024 of $18.9 million.
- Production revenue was $10.8 million, a decrease of 25% compared to the previous fiscal year.
- Engineering revenue was a record $8.3 million, an increase of 24% compared to the previous fiscal year.
- Gross margin was 30.3% compared to 36.8% in the previous fiscal year, which included a one-time sale of $600,000 in technology rights relating to a single-use medical device..
- Net loss was ($3.0) million which compared to net loss of ($0.1) million in the previous year.
- Adjusted EBITDA, defined as earnings before interest, taxes, depreciation, amortization, stock-based compensation and other income, was $(1.6) million, compared to $0.5 million in the previous fiscal year.
- Revenue was $4.7 million compared to $5.0 million in the same quarter of the previous fiscal year. Revenue of $4.7 million exceeded the implied high end of the range we announced on August 14, 2024 of 4.5 million.
- Engineering revenue was $1.9 million compared to $1.4 million in the same quarter of the previous fiscal year.
- Production revenue was $2.8 million compared to $3.6 million in the same quarter of the previous fiscal year.
- Gross margins were 21.7% compared to 35.0% in the same quarter of the previous year.
- Net loss for the quarter was ($1.4) million, compared to $(0.1) million in the same quarter of the previous year.
- Adjusted EBITDA was $(1.1) million for the quarter compared to $(0.4) million in the same quarter of the previous year.
- In May 2024, the Company announced the receipt of a $9 million production order for a high volume single-use cystoscopy surgery program. The program began production shipments of product in July, 2024.
- Subsequent to the end of the fiscal year, in August 2024 the Company announced a closing of a $1.4 million registered direct offering of common stock, which included participation from directors and officers.
"As we look forward to fiscal 2025, we expect our first quarter revenue will be in the range of $4.2 to $4.4 million, relatively flat compared to the previous year's first quarter. Revenue for the first quarter was impacted by certain challenges in the start-up and ramp of key production programs. However, these issues are mostly now resolved, and with the growth of production and ongoing strong product development sales, we expect double digit revenue growth for fiscal 2025 with significant increases in revenue beginning with the second quarter of fiscal 2025,” Dr. Forkey concluded.
The following table summarizes the fourth quarter (unaudited) and fiscal year to date results for the periods ended June 30, 2024, and 2023:
| Three Months | Year | ||||||||||||
| Ended June 30 | Ended June 30 | ||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||
| Revenues | $ | 4,716,226 | $ | 5,024,140 | $ | 19,104,350 | $ | 21,044,467 | |||||
| Gross Profit | 1,024,451 | 1,934,945 | 5,797,777 | 7,909,956 | |||||||||
| Stock Compensation Expenses | 210,393 | 139,686 | 959,784 | 884,066 | |||||||||
| Other | 2,170,410 | 2,407,733 | 7,562,326 | 7,664,437 | |||||||||
| Total Operating Expenses | 2,380,803 | 2,547,419 | 8,522,110 | 8,548,503 | |||||||||
| Operating Income (Loss) | (1,356,352 | ) | (612,475 | ) | (2,724,333 | ) | (638,548 | ) | |||||
| Net Income (Loss) | (1,411,106 | ) | (96,125 | ) | (2,951,377 | ) | (144,613 | ) | |||||
| Income (Loss) per Share | |||||||||||||
| Basic & Fully Diluted | $ | (0.23 | ) | $ | (0.02 | ) | $ | (0.49 | ) | $ | (0.03 | ) | |
| Weighted Average Common Shares Outstanding | |||||||||||||
| Basic & Fully Diluted | 6,071,846 | 5,666,034 | 6,068,329 | 5,666,034 | |||||||||
Conference Call Details
Date and Time: Monday, September 30, at 5:00pm ET
Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or (412) 317-5705.
Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available at https://app.webinar.net/0Aa98ozwG53.
Replay: A teleconference replay of the call will be available until October 3, 2024, at (877) 344-7529 or (412) 317-0088, replay access code 7367981. A webcast replay will be available at https://app.webinar.net/0Aa98ozwG53.
About Precision Optics Corporation
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Lighthouse Imaging division's electronic imaging expertise and its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company designs and manufactures next-generation product solutions for the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery, including single-use medical devices, as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies with a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.
Non-GAAP Financial Measures
Precision Optics has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the Unites States of America ("non-GAAP”). The non-GAAP financial measure is Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). Adjusted EBITDA also excludes from Net Income (Loss) the effect of stock-based compensation, restructuring and other acquisition-related items.
This non-GAAP financial measure assists Precision Optics management in comparing its operating performance over time because certain items may obscure the underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition or restructuring plans that are fundamentally different from the ongoing productivity of the Company. Precision Optics management also believes that presenting this measure allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.
About Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by the Company's management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous risk factors, including those risks discussed in the Company's annual report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement, except as required by law.
Company Contact:
PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts 01440-3338
Telephone: 978-630-1800
Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Telephone: 602-889-9700
| PRECISION OPTICS CORPORATION, INC. Consolidated Balance Sheets at June 30, 2024 and 2023 | ||||||||
| 2024 | 2023 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 405,278 | $ | 2,925,852 | ||||
| Accounts receivable, net of allowance for credit losses of $118,872 at June 30, 2024 and $606,715 at June 30, 2023 | 3,545,491 | 3,907,407 | ||||||
| Inventories | 2,868,100 | 2,776,216 | ||||||
| Prepaid expenses | 299,364 | 249,681 | ||||||
| Total current assets | 7,118,233 | 9,859,156 | ||||||
| Fixed Assets: | ||||||||
| Machinery and equipment | 3,341,194 | 3,227,481 | ||||||
| Leasehold improvements | 810,914 | 825,752 | ||||||
| Furniture and fixtures | 416,425 | 242,865 | ||||||
| 4,568,533 | 4,296,098 | |||||||
| Less-Accumulated depreciation and amortization | 4,074,960 | 3,862,578 | ||||||
| Net fixed assets | 493,573 | 433,520 | ||||||
| Operating lease right-of-use asset | 189,999 | 358,437 | ||||||
| Patents, net | 286,559 | 265,111 | ||||||
| Goodwill | 8,824,210 | 8,824,210 | ||||||
| TOTAL ASSETS | $ | 16,912,574 | $ | 19,740,434 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Revolving line of credit | $ | 1,000,000 | $ | - | ||||
| Current portion of capital lease obligation | 41,113 | 43,209 | ||||||
| Current maturities of long-term debt | 276,928 | 513,259 | ||||||
| Accounts payable | 1,397,313 | 2,432,264 | ||||||
| Customer advances | 1,172,350 | 1,174,690 | ||||||
| Accrued compensation and other | 840,662 | 927,521 | ||||||
| Operating lease liability | 178,450 | 168,677 | ||||||
| Total current liabilities | 4,906,816 | 5,259,620 | ||||||
| Capital lease obligation, net of current portion | 27,369 | 68,482 | ||||||
| Long-term debt, net of current maturities | 1,899,052 | 2,175,980 | ||||||
| Operating lease liability, net of current portion | 11,549 | 189,760 | ||||||
| Stockholders' Equity: | ||||||||
| Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding - 6,073,939 shares at June 30, 2024 and 6,066,518 shares at June 30, 2023 | 60,739 | 60,665 | ||||||
| Additional paid-in capital | 61,197,433 | 60,224,934 | ||||||
| Accumulated deficit | (51,190,384 | ) | (48,239,007 | ) | ||||
| Total stockholders' equity | 10,067,788 | 12,046,592 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 16,912,574 | $ | 19,740,434 | ||||
| PRECISION OPTICS CORPORATION, INC. Consolidated Statements of Operations for the Years Ended June 30, 2024 and 2023 | ||||||||
| 2024 | 2023 | |||||||
| Revenues | ()[\]\\.,;:\s@\"]+)*)|(\".+\"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;return b.test(a)}$(document).ready(function(){if(performance.navigation.type==2){location.reload(true)}$("iframe[data-lazy-src]").each(function(b){$(this).attr("src",$(this).attr("data-lazy-src"))});if($(".owl-article-body-images").length){$(".owl-article-body-images").owlCarousel({items:1,loop:true,center:false,dots:false,autoPlay:true,mouseDrag:false,touchDrag:false,pullDrag:false,nav:true})}var a=$("#display_full_text").val();if(a==0){$.ajax({url:"/ajax/set-article-cookie",type:"POST",data:{cmsArticleId:$("#cms_article_id").val()},dataType:"json",success:function(b){},error:function(b,d,c){}})}$(".read-full-article").on("click",function(d){d.preventDefault();var b=$(this).attr("data-cmsArticleId");var c=$(this).attr("data-productId");var f=$(this).attr("data-href");dataLayer.push({event:"paywall_click",paywall_name:"the_manila_times_premium",paywall_id:"paywall_article_"+b});$.ajax({url:"/ajax/set-article-cookie",type:"POST",data:{cmsArticleId:b,productId:c},dataType:"json",success:function(e){window.location.href=$("#BASE_URL").val()+f},error:function(e,h,g){}})});$(".article-embedded-newsletter-form .close-btn").on("click",function(){$(".article-embedded-newsletter-form").fadeOut(1000)})});$(document).on("click",".article-embedded-newsletter-form .newsletter-button",function(){var b=$(".article-embedded-newsletter-form .newsletter_email").val();var d=$("#ga_user_id").val();var c=$("#ga_user_yob").val();var a=$("#ga_user_gender").val();var e=$("#ga_user_country").val();if(validateEmail(b)){$.ajax({url:"/ajax/sendynewsletter",type:"POST",data:{email:b},success:function(f){$(".article-embedded-newsletter-form .nf-message").html(f);$(".article-embedded-newsletter-form .nf-message").addClass("show");setTimeout(function(){$(".article-embedded-newsletter-form .nf-message").removeClass("show");$(".article-embedded-newsletter-form .nf-message").html("")},6000);dataLayer.push({event:"newsletter_sub",user_id:d,product_name:"newsletter",gender:a,yob:c,country:e})},error:function(f,h,g){}})}else{$(".article-embedded-newsletter-form .nf-message").html("Please enter a valid email address.");$(".article-embedded-newsletter-form .nf-message").addClass("show");setTimeout(function(){$(".article-embedded-newsletter-form .nf-message").removeClass("show");$(".article-embedded-newsletter-form .nf-message").html("")},6000)}});$(document).on("click",".article-embedded-newsletter-form .nf-message",function(){$(this).removeClass("show");$(this).html("")});
| |||||||